TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02315677

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Intubation with nasal RAE endotracheal tube
Description: A single experienced operator with at least 5 years of clinical anesthetic experience will intubate using the standard nasal RAE endotracheal tube with bevel facing leftward.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Intubation with nasal RAE endotracheal tube
Description: A single experienced operator with at least 5 years of clinical anesthetic experience will intubate using the standard nasal RAE endotracheal tube with bevel facing leftward.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Intubation with Parker Flex-Tip endotracheal tube
Description: A single experienced operator with at least 5 years of clinical anesthetic experience will intubate using the Parker Flex-Tip endotracheal tube with the bevel facing posteriorly.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Intubation with Parker Flex-Tip endotracheal tube
Description: A single experienced operator with at least 5 years of clinical anesthetic experience will intubate using the Parker Flex-Tip endotracheal tube with the bevel facing posteriorly.
Study: NCT03731832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708
Description: Study drug will be given as a single, oral dose of 4.0 mg weekly (day 1, 8 and 15) for 3 weeks, followed by 1 week without study drug in a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708
Description: Study drug will be given as a single, oral dose of 4.0 mg weekly (day 1, 8 and 15) for 3 weeks, followed by 1 week without study drug in a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 MG Oral Capsule
Description: Study drug will be given as an oral dose of 4.0 mg on day 1 until day 21, followed by 1 week without study drug in a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 MG Oral Capsule
Description: Study drug will be given as an oral dose of 4.0 mg on day 1 until day 21, followed by 1 week without study drug in a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered as a single, oral dose of 40 mg/day weekly on day 1, 8, 15 and 22 in patients from 18 to 74 years old. For patients ≥ 75 years old dose has to be reduced to 20 mg/day with the same treatment schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered as a single, oral dose of 40 mg/day weekly on day 1, 8, 15 and 22 in patients from 18 to 74 years old. For patients ≥ 75 years old dose has to be reduced to 20 mg/day with the same treatment schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered once daily as an oral dose of 50 mg on cycle days 1 to 21, followed by one week without drug in a 28-day cycle.
Study: NCT01821378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Lurasidone 20 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Lurasidone 20 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lurasidone
Description: Lurasidone 20 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2
Description: Lurasidone 80 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2
Description: Lurasidone 80 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2
Description: Lurasidone 80 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once Daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once Daily
Study: NCT00930514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab subcutaneous injection at 1400 mg dose level, administered every 2 or 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab subcutaneous injection at 800 mg/m\^2 dose level, administered every 2 or 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab subcutaneous injection at 800 mg/m\^2 dose level, administered every 2 or 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab subcutaneous injection 625 mg/m\^2 administered every 2 or 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab intravenous infusion 375 milligram per square meter (mg/m\^2) administered every 2 or 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab intravenous infusion 375 milligram per square meter (mg/m\^2) administered every 2 or 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab subcutaneous injection 375 mg/m\^2 administered every 2 or 3 months.
Study: NCT02563093

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative
Description: 0.5 mL, Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulation
Description: 0.1 mL, Intradermal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone High-Dose vaccine, 2015-2016 formulation
Description: 0.5 mL, Intramuscular
Study: NCT01158651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001 (Everolimus)
Description: If you take part in this research study, you will be given a participant diary for each treatment course to help you keep track of when you take your RAD001. You will be required to bring the completed diary at each scheduled visit. A treatment course lasts 4 weeks and there will not be any breaks between courses. You may stay on study for a total of 12 courses (48 weeks).~You will take the study medication (tablets) by mouth, once a day during each course for as long as you are participating in this study. You will also be required to take an antibiotic during treatment to prevent infection.
Study: NCT03296462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip external rotation exercise
Description: Standardised HER exercise training by physiotherapist (plus video recording of exercises)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip external rotation exercise
Description: Standardised HER exercise training by physiotherapist (plus video recording of exercises)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercise
Description: Standardised PFM exercise training by physiotherapist (plus video recording of exercises)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle exercise
Description: Standardised PFM exercise training by physiotherapist (plus video recording of exercises)
Study: NCT01264367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevudine
Description: 30mg,QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clevudine + Peg-interferon
Description: 30mg, QD(for 24 weeks) + 180mcg,QW(for 24 weeks)
Study: NCT03480256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390
Description: SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.Pyrotinib is an irreversible pan-ErbB inhibitor which shows promising antitumour activity in patients with HER2-positive metastatic gastric cancer
Study: NCT03643120

Intervention type: OTHER
Group type: OTHER
Intervention: Qualitative interview
Description: Explorative study of gender dysphoria.
Study: NCT01969825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Massage
Study: NCT05961280

Intervention type: PROCEDURE
Intervention: Mastectomy with sentinel lymph node biopsy
Study: NCT04540133

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone 0.5mg/5ml solution
Description: Patient with oral ulcerative conditions will be asked to rinse with dexamethasone 0.5mg/5ml solution three times a day for 4 weeks and expectorate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone 0.5mg/5ml solution in Mucolox™
Description: Patient with oral ulcerative conditions will be asked to rinse with dexamethasone 0.5mg/5ml solution in Mucolox™ three times a day for 4 weeks and expectorate
Study: NCT01717963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone intramuscular suspension
Description: A standard dosage of 380 mg / month of naltrexone intramuscular suspension will be administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine-naloxone
Description: Buprenorphine-naloxone is administered daily and provided in accordance with existing guidelines for OMT in Norway (treatment-as-usual).
Study: NCT01875822

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Super-Curcumin
Description: The investigators are comparing the effects of the two dosages of Super-Curcumin@ capsules in the sample of subjects diagnosed as DSM IV-R schizophrenia
Study: NCT02217189

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zinc sulfate
Description: The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
Study: NCT04042558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab
Description: 4 cycles of induction every 3 weeks of cisplatine,pemetrexed, atezolizumab + bevacizumab and patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed +/- Bevacizumab administered at the same dosage on 3-week cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin + Pemetrexed + Atezolizumab
Description: Carboplatin + Pemetrexed + Atezolizumab
Study: NCT03272542

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic: soluble corn fiber
Description: prebiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: maltodextrin
Description: placebo
Study: NCT04580862

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-surgical endodontic retreatment in single visit
Description: Full medical and dental history using a schematic dental chart, will be obtained from all patients treated during this study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical endodontic retreatment in single visit
Description: Full medical and dental history using a schematic dental chart, will be obtained from all patients treated during this study.
Study: NCT04845360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pressure transducer (PSL-200GL, Kyowa Electronic Instrument Co. Ltd., Japan)
Description: The device was fixed on the patient's skin with Scotch™ tape, along with an adjustable belt with a small button to give suitable pressure on the transducer.
Study: NCT04008355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZP2006 oral solution
Description: Once daily intake in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZP2006 oral solution
Description: Once daily intake in the morning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral solution
Description: Once daily intake in the morning
Study: NCT02157350

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Panretinal laser photocoagulation
Description: Panretinal photocoagulation. Laser energy is given to the retina in two sittings, carefully avoiding the macular. The energy are placed 2 to 3 disc diameters away from the macula and the disc outside the arcades and extended peripherally upto the equator and beyond.
Study: NCT03991091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: discontinuation of oxytocin administration
Description: Discontinuation of oxytocin administration at the beginning of the active phase of the 1st stage of labor, i.e. oxytocin infusion will be stopped beyond a cervical dilatation of 6cm. In the experimental group, oxytocin can be re-started, if necessary, after 2 hours of arrest of labor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continuation of oxytocin administration
Description: continuation of oxytocin administration
Study: NCT00559585

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous (SC) Abatacept
Description: Participants received 125 mg weekly SC abatacept injections (with an intravenous \[IV\] abatacept loading dose on Day 1, based on weight). A double-dummy design was used to protect the blind, thus, participants also received IV injections of placebo (IV Placebo) with the exception that on Day 1 a loading dose of IV abatacept replaced the IV Placebo treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous (IV) Abatacept
Description: Participants received IV abatacept infusions on Days 1, 15, 29, and every 28 days, thereafter. A double-dummy design was used to protect the blind, thus, participants also received SC injections of placebo (SC Placebo).~500mg (for body weight up to 60 kg)~750 mg (body weight between 61 and 100 kg)~1g (body weight above 100 kg)infusions
Study: NCT02746666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist's behavioral intervention
Description: Pharmacist's 30 min counselling on antiemetic therapy, causes of nausea or vomiting and ways to prevent them during chemotherapy.
Study: NCT01536236

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ANS Eon™ Implantable Pulse Generator (Permanent Implant)
Description: Appropriate programming based on subject's preference of programs.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ANS Eon™ Implantable Pulse Generator (Permanent Implant)
Description: Appropriate programming based on subject's preference of programs.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ANS Eon™ Implantable Pulse Generator (Permanent Implant)
Description: Appropriate programming based on subject's preference of programs.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03886792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Triggered reinforcement
Description: This group will participate in a home-based experimental intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray secured anterior to the trunk. This intervention will involve reinforcement of biceps muscle activation in the affected arm if the infant generates a muscle contraction above a pre-set threshold (V). The threshold needed to trigger a toy to move and make sounds (reinforcement) will be set at baseline as determined by surface electromyography (SEMG). During the training time-points, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Social interaction
Description: This group will participate in a home-based dose-equivalent control intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray. This control program will combine social interaction between infant/parent with the opportunity for self-initiated play with toys repeatedly placed on the tray. A toy will be placed in front of the infant seat and tray but it will not be connected to the SEMG unit nor will the infant have an SEMG electrode attached over the biceps. During the intervention, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
Study: NCT04147325

Intervention type: DRUG
Intervention: Antiretroviral Therapy
Description: ART will be administered chosen by the investigator according to country/ local standards/ guidelines/ available ARV for current treatment guidelines for rapid initiation.

Intervention type: DRUG
Intervention: Antiretroviral Therapy
Description: ART will be administered chosen by the investigator according to country/ local standards/ guidelines/ available ARV for current treatment guidelines for rapid initiation.
Study: NCT03187171

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Allograft Fusion
Description: ACDF is a surgical technique used to treat a variety of cervical spine disorders, such as nerve root or spinal cord compression, cervical spondylosis, and cervical spinal stenosis. The anterior approach to the cervical spine for discectomy and fusion by the insertion of an autologous iliac crest tricortical bone graft was first described by Robinson and Smith in 1955. In 1958, Cloward described a wide anterior cylindrical discectomy performed with a special reamer combined with anterior fusion by the insertion of autologous iliac bone graft of the same shape. At Duke University Health Systems, both allografts and Cohere porous PEEK fusion device are used for ACDF.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cohere PEEK Fusion Group
Description: Bagby et al. developed the first interbody fusion cage. Cages of different shapes and materials are used to perform ACDF which, in some cases, could be associated with plate fixation. At Duke University Health Systems, both allografts and Cohere porous PEEK fusion device are used for ACDF.
Study: NCT03691090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 200mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel 175mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: paclitaxel 175mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: cisplatin 75mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: cisplatin 75mg/m2
Study: NCT01438151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remicade
Description: The first potential for dose augmentation will be at infusion #3 (visit 1 and 2 patients will receive 5 mg/kg). Patients will be assessed at each infusion visit for response defined as a reduction in HBI score by 2 or more points from prior visit (unless in remission; HBI score of 4 or less). Patients with a response will be maintained at the dose where response was achieved. If there is no response to treatment, or flare at any visit (beginning at visit #3), infliximab dose or dosing frequency will be increased in a gradual fashion, up to a maximum of 15 mg/kg every 6 weeks, until response is achieved.
Study: NCT00769860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arimoclomol
Description: Arimoclomol 100 mg TID for 4 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 4 months
Study: NCT02812901

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cardiac surgery scheduled in the morning
Description: cardiac surgery scheduled in the morning

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cardiac surgery scheduled in the afternoon
Description: cardiac surgery scheduled in the afternoon
Study: NCT02173041

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prevention Awareness Groups (PAG)

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Study: NCT03931733

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Therapy
Description: Single thirty minute receptive music therapy intervention.
Study: NCT01026142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m2 po twice daily for 14 days every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1250 mg/m2 po twice daily for 14 days every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840 mg iv loading, then 420 mg iv every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks
Study: NCT04151953

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample collection
Description: Blood sample collection for markers of myocardial injury
Study: NCT01829425

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticholinergic medications
Description: The study will use either of two standard, long acting anti-cholinergic medications and dosages. Pharmacotherapy counseling sessions will also be administered over 8 weeks by trained research personnel. Pharmacotherapy counseling sessions will be audio-recorded and one or more sessions will be reviewed by study personnel to ensure that the medication counselor administers the sessions in a standardized fashion. Pill counts will be performed at the conclusion of the 8 weeks of pharmacotherapy counseling. Subjects will be provided the medication for 1 year.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypnotherapy
Description: Hypnotherapy will be administered approximately weekly over 8 weeks by certified, trained clinical hypnotherapists. Sessions will be audio-recorded and one or more sessions will be reviewed by study personnel to ensure that the hypnotherapist administers the hypnotherapy session in a standardized fashion.Subjects will receive or download a digital recording specially prepared for them to for home practice of hypnotherapy sessions.Following the 8 weeks of therapy, subjects will be encouraged to continue to practice self-hypnosis and/or listen to their home practice digital recording and this practice will be tracked for the 1 year duration of the study.
Study: NCT04178967

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Subcutaneous injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous Injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous Injection
Study: NCT01554735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and diet
Description: 24 weeks of exercise and diet counselling